{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:24:27Z","timestamp":1792268667501,"version":"4.4.0"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1038\/s41569-022-00682-0","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T11:08:49Z","timestamp":1647601729000},"page":"353-363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["Targeting the sarcomere in inherited cardiomyopathies"],"prefix":"10.1038","volume":"19","author":[{"given":"Sarah J.","family":"Lehman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Crocini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1470-4810","authenticated-orcid":false,"given":"Leslie A.","family":"Leinwand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"682_CR1","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/0092-8674(90)90274-I","volume":"62","author":"AA Geisterfer-Lowrance","year":"1990","unstructured":"Geisterfer-Lowrance, A. A. et al. A molecular basis for familial hypertrophic cardiomyopathy: a \u03b2 cardiac myosin heavy chain gene missense mutation. Cell 62, 999\u20131006 (1990).","journal-title":"Cell"},{"key":"682_CR2","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1056\/NEJM200012073432304","volume":"343","author":"M Kamisago","year":"2000","unstructured":"Kamisago, M. et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N. Engl. J. Med. 343, 1688\u20131696 (2000).","journal-title":"N. Engl. J. Med."},{"key":"682_CR3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa1110186","volume":"366","author":"D Herman","year":"2012","unstructured":"Herman, D. et al. Truncations of titin causing dilated cardiomyopathy. N. Engl. J. Med. 366, 619\u2013628 (2012).","journal-title":"N. Engl. J. Med."},{"key":"682_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/CIRCRESAHA.116.309396","volume":"121","author":"E McNally","year":"2017","unstructured":"McNally, E. & Mestroni, L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ. Res. 121, 731\u2013748 (2017).","journal-title":"Circ. Res."},{"key":"682_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00424-019-02259-2","volume":"471","author":"J Spudich","year":"2019","unstructured":"Spudich, J. Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. Pflug. Arch. 471, 701\u2013717 (2019).","journal-title":"Pflug. Arch."},{"key":"682_CR6","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"C Ho","year":"2018","unstructured":"Ho, C. et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe). Circulation 138, 1387\u20131398 (2018).","journal-title":"Circulation"},{"key":"682_CR7","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1161\/CIRCRESAHA.119.313569","volume":"124","author":"G Repetti","year":"2019","unstructured":"Repetti, G., Toepfer, C., Seidman, J. & Seidman, C. Novel therapies for prevention and early treatment of cardiomyopathies. Circ. Res. 124, 1536\u20131550 (2019).","journal-title":"Circ. Res."},{"key":"682_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1586\/erc.13.46","volume":"11","author":"S Said","year":"2013","unstructured":"Said, S., Dearani, J., Ommen, S. & Schaff, H. Surgical treatment of hypertrophic cardiomyopathy. Expert Rev. Cardiovasc. Ther. 11, 617\u2013627 (2013).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"682_CR9","first-page":"30","volume":"2018","author":"J Mateo","year":"2018","unstructured":"Mateo, J. & Gimeno, J. Alcohol septal ablation in hypertrophic cardiomyopathy. Glob. Cardiol. Sci. Pract. 2018, 30 (2018).","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"682_CR10","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/phar.1664","volume":"35","author":"N Verlinden","year":"2015","unstructured":"Verlinden, N. & Coons, J. Disopyramide for hypertrophic cardiomyopathy: a pragmatic reappraisal of an old drug. Pharmacotherapy 35, 1164\u20131172 (2015).","journal-title":"Pharmacotherapy"},{"key":"682_CR11","doi-asserted-by":"publisher","first-page":"100933","DOI":"10.1016\/j.eclinm.2021.100933","volume":"36","author":"R Cardoso","year":"2021","unstructured":"Cardoso, R. et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinicalMedicine 36, 100933 (2021).","journal-title":"EClinicalMedicine"},{"key":"682_CR12","doi-asserted-by":"publisher","first-page":"9599","DOI":"10.3390\/ijms21249599","volume":"21","author":"K Alsulami","year":"2020","unstructured":"Alsulami, K. & Marston, S. Small molecules acting on myofilaments as treatments for heart and skeletal muscle diseases. Int. J. Mol. Sci. 21, 9599 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"682_CR13","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1126\/science.1200113","volume":"331","author":"FI Malik","year":"2011","unstructured":"Malik, F. I. et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 331, 1439\u20131443 (2011).","journal-title":"Science"},{"key":"682_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green, E. M. et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351, 617\u2013621 (2016).","journal-title":"Science"},{"key":"682_CR15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0002-9343(63)90131-1","volume":"35","author":"H Price","year":"1963","unstructured":"Price, H. The skeletal muscle fiber in the light of electron microscope studies: a review. Am. J. Med. 35, 589\u2013605 (1963).","journal-title":"Am. J. Med."},{"key":"682_CR16","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1152\/physrev.2000.80.2.853","volume":"80","author":"A Gordon","year":"2000","unstructured":"Gordon, A., Homsher, E. & Regnier, M. Regulation of contraction in striated muscle. Physiol. Rev. 80, 853\u2013924 (2000).","journal-title":"Physiol. Rev."},{"key":"682_CR17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/nature03920","volume":"436","author":"JL Woodhead","year":"2005","unstructured":"Woodhead, J. L. et al. Atomic model of a myosin filament in the relaxed state. Nature 436, 1195\u20131199 (2005).","journal-title":"Nature"},{"key":"682_CR18","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1091\/mbc.e08-02-0206","volume":"19","author":"H Jung","year":"2008","unstructured":"Jung, H., Komatsu, S., Ikebe, M. & Craig, R. Head-head and head-tail interaction: a general mechanism for switching off myosin II activity in cells. Mol. Biol. Cell 19, 3234\u20133242 (2008).","journal-title":"Mol. Biol. Cell"},{"key":"682_CR19","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1073\/pnas.0708912105","volume":"105","author":"M Zoghbi","year":"2008","unstructured":"Zoghbi, M., Woodhead, J., Moss, R. & Craig, R. Three-dimensional structure of vertebrate cardiac muscle myosin filaments. Proc. Natl Acad. Sci. USA 105, 2386\u20132390 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"682_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1073\/pnas.0909468107","volume":"107","author":"M Stewart","year":"2010","unstructured":"Stewart, M., Franks-Skiba, K., Chen, S. & Cooke, R. Myosin ATP turnover rate is a mechanism involved in thermogenesis in resting skeletal muscle fibers. Proc. Natl Acad. Sci. USA 107, 430\u2013435 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"682_CR21","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/j.bpj.2011.02.061","volume":"100","author":"P Hooijman","year":"2011","unstructured":"Hooijman, P., Stewart, M. & Cooke, R. A new state of cardiac myosin with very slow ATP turnover: a potential cardioprotective mechanism in the heart. Biophys. J. 100, 1969\u20131976 (2011).","journal-title":"Biophys. J."},{"key":"682_CR22","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","volume":"141","author":"C Toepfer","year":"2020","unstructured":"Toepfer, C. et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation 141, 828\u2013842 (2020).","journal-title":"Circulation"},{"key":"682_CR23","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.jmb.2016.01.027","volume":"428","author":"L Alamo","year":"2016","unstructured":"Alamo, L. et al. Conserved intramolecular interactions maintain myosin interacting-heads motifs explaining tarantula muscle super-relaxed state structural basis. J. Mol. Biol. 428, 1142\u20131164 (2016).","journal-title":"J. Mol. Biol."},{"key":"682_CR24","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.3390\/ijms19092643","volume":"19","author":"W Ma","year":"2018","unstructured":"Ma, W., Gong, H. & Irving, T. Myosin head configurations in resting and contracting murine skeletal muscle. Int. J. Mol. Sci. 19, 2643 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"682_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06191-4","volume":"9","author":"J Robert-Paganin","year":"2018","unstructured":"Robert-Paganin, J., Auguin, D. & Houdusse, A. Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition. Nat. Commun. 9, 4019 (2018).","journal-title":"Nat. Commun."},{"key":"682_CR26","doi-asserted-by":"publisher","first-page":"101157","DOI":"10.1016\/j.jbc.2021.101157","volume":"297","author":"S Chu","year":"2021","unstructured":"Chu, S., Muretta, J. & Thomas, D. Direct detection of the myosin super-relaxed state and interacting-heads motif in solution. J. Biol. Chem. 297, 101157 (2021).","journal-title":"J. Biol. Chem."},{"key":"682_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/biology8030067","volume":"8","author":"C Knupp","year":"2019","unstructured":"Knupp, C., Morris, E. & Squire, J. The interacting head motif structure does not explain the X-ray diffraction patterns in relaxed vertebrate (bony fish) skeletal muscle and insect (Lethocerus) flight muscle. Biology 8, 67 (2019).","journal-title":"Biology"},{"key":"682_CR28","doi-asserted-by":"publisher","first-page":"8177","DOI":"10.1073\/pnas.1920632117","volume":"117","author":"E Brunello","year":"2020","unstructured":"Brunello, E. et al. Myosin filament-based regulation of the dynamics of contraction in heart muscle. Proc. Natl Acad. Sci. USA 117, 8177\u20138186 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"682_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s12551-021-00840-7","volume":"13","author":"C Crocini","year":"2021","unstructured":"Crocini, C. & Gotthardt, M. Cardiac sarcomere mechanics in health and disease. Biophys. Rev. 13, 637\u2013652 (2021).","journal-title":"Biophys. Rev."},{"key":"682_CR30","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.202012726","volume":"153","author":"S Rahmanseresht","year":"2021","unstructured":"Rahmanseresht, S. et al. The N terminus of myosin-binding protein C extends toward actin filaments in intact cardiac muscle. J. Gen. Physiol. 153, e202012726 (2021).","journal-title":"J. Gen. Physiol."},{"key":"682_CR31","doi-asserted-by":"publisher","first-page":"6828","DOI":"10.1073\/pnas.1816480116","volume":"116","author":"A Inchingolo","year":"2019","unstructured":"Inchingolo, A., Previs, S., Previs, M., Warshaw, D. & Kad, N. Revealing the mechanism of how cardiac myosin-binding protein C N-terminal fragments sensitize thin filaments for myosin binding. Proc. Natl Acad. Sci. USA 116, 6828\u20136835 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"682_CR32","doi-asserted-by":"publisher","first-page":"21882","DOI":"10.1073\/pnas.1910549116","volume":"116","author":"A Li","year":"2019","unstructured":"Li, A. et al. Skeletal MyBP-C isoforms tune the molecular contractility of divergent skeletal muscle systems. Proc. Natl Acad. Sci. USA 116, 21882\u201321892 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"682_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1161\/CIRCRESAHA.116.300561","volume":"116","author":"R Moss","year":"2015","unstructured":"Moss, R., Fitzsimons, D. & Ralphe, J. Cardiac MyBP-C regulates the rate and force of contraction in mammalian myocardium. Circ. Res. 116, 183\u2013192 (2015).","journal-title":"Circ. Res."},{"key":"682_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.yjmcc.2016.03.009","volume":"94","author":"J McNamara","year":"2016","unstructured":"McNamara, J. et al. Ablation of cardiac myosin binding protein-C disrupts the super-relaxed state of myosin in murine cardiomyocytes. J. Mol. Cell Cardiol. 94, 65\u201371 (2016).","journal-title":"J. Mol. Cell Cardiol."},{"key":"682_CR35","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.bpj.2020.07.036","volume":"119","author":"S Nelson","year":"2020","unstructured":"Nelson, S., Li, A., Beck-Previs, S., Kennedy, G. & Warshaw, D. Imaging ATP consumption in resting skeletal muscle: one molecule at a time. Biophys. J. 119, 1050\u20131055 (2020).","journal-title":"Biophys. J."},{"key":"682_CR36","doi-asserted-by":"publisher","first-page":"E1355","DOI":"10.1073\/pnas.1614020114","volume":"114","author":"R Kensler","year":"2017","unstructured":"Kensler, R., Craig, R. & Moss, R. Phosphorylation of cardiac myosin binding protein C releases myosin heads from the surface of cardiac thick filaments. Proc. Natl Acad. Sci. USA 114, E1355\u2013E1364 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"682_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax0069","volume":"6","author":"S Sarkar","year":"2021","unstructured":"Sarkar, S. et al. The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin. Sci. Adv. 6, eaax0069 (2021).","journal-title":"Sci. Adv."},{"key":"682_CR38","doi-asserted-by":"publisher","first-page":"11731","DOI":"10.1073\/pnas.1821660116","volume":"116","author":"J McNamara","year":"2019","unstructured":"McNamara, J., Singh, R. & Sadayappan, S. Cardiac myosin binding protein-C phosphorylation regulates the super-relaxed state of myosin. Proc. Natl Acad. Sci. USA 116, 11731\u201311736 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"682_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41569-021-00608-2","volume":"19","author":"R Walsh","year":"2022","unstructured":"Walsh, R., Offerhaus, J., Tadros, R. & Bezzina, C. Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies. Nat. Rev. Cardiol. 19, 151\u2013167 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"682_CR40","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"A Marian","year":"2017","unstructured":"Marian, A. & Braunwald, E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ. Res. 121, 749\u2013770 (2017).","journal-title":"Circ. Res."},{"key":"682_CR41","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00424-018-2226-9","volume":"471","author":"A Glazier","year":"2019","unstructured":"Glazier, A., Thompson, A. & Day, S. Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy. Pflug. Arch. 471, 781\u2013793 (2019).","journal-title":"Pflug. Arch."},{"key":"682_CR42","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1172\/JCI3880","volume":"102","author":"Q Yang","year":"1998","unstructured":"Yang, Q. et al. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J. Clin. Invest. 102, 1292\u20131300 (1998).","journal-title":"J. Clin. Invest."},{"key":"682_CR43","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133782","volume":"5","author":"A Helms","year":"2020","unstructured":"Helms, A. et al. Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy. JCI Insight 5, e133782 (2020).","journal-title":"JCI Insight"},{"key":"682_CR44","doi-asserted-by":"publisher","first-page":"bio.057646","DOI":"10.1242\/bio.057646","volume":"10","author":"M Schmid","year":"2021","unstructured":"Schmid, M. & Toepfer, C. Cardiac myosin super relaxation (SRX): a perspective on fundamental biology, human disease and therapeutics. Biol. Open 10, bio.057646 (2021).","journal-title":"Biol. Open"},{"key":"682_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180064","volume":"12","author":"J McNamara","year":"2017","unstructured":"McNamara, J. et al. MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy. PLoS ONE 12, e0180064 (2017).","journal-title":"PLoS ONE"},{"key":"682_CR46","doi-asserted-by":"publisher","first-page":"E8143","DOI":"10.1073\/pnas.1805259115","volume":"115","author":"R Anderson","year":"2018","unstructured":"Anderson, R. et al. Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc. Natl Acad. Sci. USA 115, E8143\u2013E8152 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"682_CR47","doi-asserted-by":"publisher","first-page":"E7486","DOI":"10.1073\/pnas.1720342115","volume":"115","author":"J Rohde","year":"2018","unstructured":"Rohde, J., Roopnarine, O., Thomas, D. & Muretta, J. Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin. Proc. Natl Acad. Sci. USA 115, E7486\u2013E7494 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"682_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10555-9","volume":"10","author":"A Adhikari","year":"2019","unstructured":"Adhikari, A. et al. \u03b2-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity. Nat. Commun. 10, 2685 (2019).","journal-title":"Nat. Commun."},{"key":"682_CR49","doi-asserted-by":"publisher","first-page":"100114","DOI":"10.1074\/jbc.RA120.016506","volume":"296","author":"S Gollapudi","year":"2021","unstructured":"Gollapudi, S., Yu, M., Gan, Q. & Nag, S. Synthetic thick filaments: a new avenue for better understanding the myosin super-relaxed state in healthy, diseased, and mavacamten-treated cardiac systems. J. Biol. Chem. 296, 100114 (2021).","journal-title":"J. Biol. Chem."},{"key":"682_CR50","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.24634","volume":"6","author":"L Alamo","year":"2017","unstructured":"Alamo, L. et al. Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes. eLife 6, e24634 (2017).","journal-title":"eLife"},{"key":"682_CR51","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/HCO.0b013e328337ba52","volume":"25","author":"L Dellefave","year":"2010","unstructured":"Dellefave, L. & McNally, E. The genetics of dilated cardiomyopathy. Curr. Opin. Cardiol. 25, 198\u2013204 (2010).","journal-title":"Curr. Opin. Cardiol."},{"key":"682_CR52","doi-asserted-by":"publisher","first-page":"259ra144","DOI":"10.1126\/scitranslmed.3010018","volume":"6","author":"E Ceco","year":"2014","unstructured":"Ceco, E. et al. Targeting latent TGF\u03b2 release in muscular dystrophy. Sci. Transl Med. 6, 259ra144 (2014).","journal-title":"Sci. Transl Med."},{"key":"682_CR53","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ejhg.2013.16","volume":"21","author":"R Roncarati","year":"2013","unstructured":"Roncarati, R. et al. Doubly heterozygous LMNA and TTN mutations revealed by exome sequencing in a severe form of dilated cardiomyopathy. Eur. J. Hum. Genet. 21, 1105\u20131111 (2013).","journal-title":"Eur. J. Hum. Genet."},{"key":"682_CR54","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/ng815","volume":"30","author":"B Gerull","year":"2002","unstructured":"Gerull, B. et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat. Genet. 30, 201\u2013204 (2002).","journal-title":"Nat. Genet."},{"key":"682_CR55","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrcardio.2017.190","volume":"15","author":"J Ware","year":"2017","unstructured":"Ware, J. & Cook, S. Role of titin in cardiomyopathy: from DNA variants to patient stratification. Nat. Rev. Cardiol. 15, 241\u2013252 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"682_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd7287","volume":"13","author":"Q McAfee","year":"2021","unstructured":"McAfee, Q. et al. Truncated titin proteins in dilated cardiomyopathy. Sci. Transl Med. 13, eabd7287 (2021).","journal-title":"Sci. Transl Med."},{"key":"682_CR57","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/FJC.0000000000000113","volume":"64","author":"L Nagy","year":"2014","unstructured":"Nagy, L., Pollesello, P. & Papp, Z. Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus. J. Cardiovasc. Pharmacol. 64, 199\u2013208 (2014).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"682_CR58","first-page":"188","volume":"31","author":"JW Herzig","year":"1981","unstructured":"Herzig, J. W., Feile, K. & Ruegg, J. C. Activating effects of AR-L 115 BS on the Ca2+ sensitive force, stiffness and unloaded shortening velocity (Vmax) in isolated contractile structures from mammalian heart muscle. Arzneimittelforschung 31, 188\u2013191 (1981).","journal-title":"Arzneimittelforschung"},{"key":"682_CR59","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1161\/01.RES.51.3.290","volume":"51","author":"RJ Solaro","year":"1982","unstructured":"Solaro, R. J. & Ruegg, J. C. Stimulation of Ca++ binding and ATPase activity of dog cardiac myofibrils by AR-L 115BS, a novel cardiotonic agent. Circ. Res. 51, 290\u2013294 (1982).","journal-title":"Circ. Res."},{"key":"682_CR60","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/978-1-4615-3362-7_63","volume":"311","author":"A Raasmaja","year":"1992","unstructured":"Raasmaja, A. et al. Biochemical properties of OR-1259 \u2013 a positive inotropic and vasodilatory compound with an antiarrhythmic effect. Adv. Exp. Med. Biol. 311, 423 (1992).","journal-title":"Adv. Exp. Med. Biol."},{"key":"682_CR61","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/0022-2828(95)90009-8","volume":"27","author":"H Haikala","year":"1995","unstructured":"Haikala, H. et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J. Mol. Cell Cardiol. 27, 1859\u20131866 (1995).","journal-title":"J. Mol. Cell Cardiol."},{"key":"682_CR62","doi-asserted-by":"publisher","first-page":"28584","DOI":"10.1016\/S0021-9258(19)61945-9","volume":"269","author":"P Pollesello","year":"1994","unstructured":"Pollesello, P. et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J. Biol. Chem. 269, 28584\u201328590 (1994).","journal-title":"J. Biol. Chem."},{"key":"682_CR63","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1023\/B:MCBI.0000049141.37823.19","volume":"266","author":"T Sorsa","year":"2004","unstructured":"Sorsa, T., Pollesello, P. & Solaro, R. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c. Mol. Cell Biochem. 266, 87\u2013107 (2004).","journal-title":"Mol. Cell Biochem."},{"key":"682_CR64","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1074\/jbc.M007484200","volume":"276","author":"T Sorsa","year":"2001","unstructured":"Sorsa, T. et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J. Biol. Chem. 276, 9337\u20139343 (2001).","journal-title":"J. Biol. Chem."},{"issue":"Suppl. 1","key":"682_CR65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/00005344-199506261-00003","volume":"26","author":"H Haikala","year":"1995","unstructured":"Haikala, H. & Linden, I. Mechanisms of action of calcium-sensitizing drugs. J. Cardiovasc. Pharmacol. 26 (Suppl. 1), 10\u201319 (1995).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"682_CR66","first-page":"277","volume":"280","author":"P Boknik","year":"1997","unstructured":"Boknik, P. et al. Mechanisms of the contractile effects of levosimendan in the mammalian heart. J. Pharmacol. Exp. Ther. 280, 277\u2013283 (1997).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"682_CR67","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejphar.2003.12.005","volume":"486","author":"S Szilagyi","year":"2004","unstructured":"Szilagyi, S. et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur. J. Pharmacol. 486, 67\u201374 (2004).","journal-title":"Eur. J. Pharmacol."},{"key":"682_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115547","volume":"10","author":"O Orstavik","year":"2015","unstructured":"Orstavik, O. et al. The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium. PLoS ONE 10, e0115547 (2015).","journal-title":"PLoS ONE"},{"key":"682_CR69","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","volume":"360","author":"F Follath","year":"2002","unstructured":"Follath, F. et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360, 196\u2013202 (2002).","journal-title":"Lancet"},{"key":"682_CR70","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","volume":"297","author":"A Mebazaa","year":"2007","unstructured":"Mebazaa, A. et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297, 1883\u20131891 (2007).","journal-title":"JAMA"},{"key":"682_CR71","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa1616325","volume":"376","author":"G Landoni","year":"2017","unstructured":"Landoni, G. et al. Levosimendan for hemodynamic support after cardiac surgery. N. Engl. J. Med. 376, 2021\u20132031 (2017).","journal-title":"N. Engl. J. Med."},{"key":"682_CR72","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1616218","volume":"376","author":"RH Mehta","year":"2017","unstructured":"Mehta, R. H. et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N. Engl. J. Med. 376, 2032\u20132042 (2017).","journal-title":"N. Engl. J. Med."},{"key":"682_CR73","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2017.9973","volume":"318","author":"B Cholley","year":"2017","unstructured":"Cholley, B. et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA 318, 548\u2013556 (2017).","journal-title":"JAMA"},{"key":"682_CR74","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","volume":"1","author":"M Packer","year":"2013","unstructured":"Packer, M. et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 1, 103\u2013111 (2013).","journal-title":"JACC Heart Fail."},{"key":"682_CR75","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/ejhf.872","volume":"19","author":"V Harjola","year":"2017","unstructured":"Harjola, V. et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. J. Heart Fail. 19, 821\u2013836 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"682_CR76","unstructured":"Reagan, J. D. et al. The novel myotrope, AMG 594, is a small-molecule cardiac troponin activator that increases cardiac contractility in vitro and in vivo. Presented at the Keystone Symposium on Charting a New Course for Heart Failure: From Discovery to Data (Amgen and Cytokinetics, 2020)."},{"key":"682_CR77","first-page":"A9199","volume":"144","author":"H He","year":"2021","unstructured":"He, H. et al. A novel small molecule troponin activator increases cardiac contractile function without negative impact on energetics or diastolic function. Circ. Heart Fail. 144, A9199 (2021).","journal-title":"Circ. Heart Fail."},{"key":"682_CR78","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1021\/ml100138q","volume":"1","author":"BP Morgan","year":"2010","unstructured":"Morgan, B. P. et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin. ACS Med. Chem. Lett. 1, 472\u2013477 (2010).","journal-title":"ACS Med. Chem. Lett."},{"key":"682_CR79","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1021\/bi5015166","volume":"54","author":"Y Liu","year":"2015","unstructured":"Liu, Y., White, H. D., Belknap, B., Winkelmann, D. A. & Forgacs, E. Omecamtiv mecarbil modulates the kinetic and motile properties of porcine \u03b2-cardiac myosin. Biochemistry 54, 1963\u20131975 (2015).","journal-title":"Biochemistry"},{"key":"682_CR80","doi-asserted-by":"publisher","first-page":"E1796","DOI":"10.1073\/pnas.1611698114","volume":"114","author":"J Rohde","year":"2017","unstructured":"Rohde, J., Thomas, D. & Muretta, J. Heart failure drug changes the mechanoenzymology of the cardiac myosin powerstroke. Proc. Natl Acad. Sci. USA 114, E1796\u2013E1804 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"682_CR81","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1074\/jbc.M116.748780","volume":"292","author":"AM Swenson","year":"2017","unstructured":"Swenson, A. M. et al. Omecamtiv mecarbil enhances the duty ratio of human \u03b2-cardiac myosin resulting in increased calcium sensitivity and slowed force development in cardiac muscle. J. Biol. Chem. 292, 3768\u20133778 (2017).","journal-title":"J. Biol. Chem."},{"key":"682_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06193-2","volume":"9","author":"MS Woody","year":"2018","unstructured":"Woody, M. S. et al. Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke. Nat. Commun. 9, 3838 (2018).","journal-title":"Nat. Commun."},{"key":"682_CR83","doi-asserted-by":"publisher","first-page":"167295","DOI":"10.1016\/j.jmb.2021.167295","volume":"433","author":"S Gollapudi","year":"2021","unstructured":"Gollapudi, S. et al. Two classes of myosin inhibitors, blebbistatin, and mavacamten, stabilize \u03b2-cardiac myosin in different structural and functional states. J. Mol. Biol. 433, 167295 (2021).","journal-title":"J. Mol. Biol."},{"key":"682_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00176-5","volume":"8","author":"V Planelles-Herrero","year":"2017","unstructured":"Planelles-Herrero, V., Hartman, J., Robert-Paganin, J., Malik, F. & Houdusse, A. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat. Commun. 8, 190 (2017).","journal-title":"Nat. Commun."},{"key":"682_CR85","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0006-3495(93)81110-X","volume":"65","author":"DF McKillop","year":"1993","unstructured":"McKillop, D. F. & Geeves, M. A. Regulation of the interaction between actin and myosin subfragment 1: evidence for three states of the thin filament. Biophys. J. 65, 693\u2013701 (1993).","journal-title":"Biophys. J."},{"key":"682_CR86","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1161\/CIRCHEARTFAILURE.114.002152","volume":"8","author":"JP Bakkehaug","year":"2015","unstructured":"Bakkehaug, J. P. et al. Myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin atpase activity. Circ. Heart Fail. 8, 766\u2013775 (2015).","journal-title":"Circ. Heart Fail."},{"key":"682_CR87","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1161\/CIRCHEARTFAILURE.109.930321","volume":"3","author":"YT Shen","year":"2010","unstructured":"Shen, Y. T. et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ. Heart Fail. 3, 522\u2013527 (2010).","journal-title":"Circ. Heart Fail."},{"key":"682_CR88","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0140-6736(11)61219-1","volume":"378","author":"JR Teerlink","year":"2011","unstructured":"Teerlink, J. R. et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 378, 667\u2013675 (2011).","journal-title":"Lancet"},{"key":"682_CR89","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","volume":"388","author":"J Teerlink","year":"2016","unstructured":"Teerlink, J. et al. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 388, 2895\u20132903 (2016).","journal-title":"Lancet"},{"key":"682_CR90","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/ejhf.2181","volume":"23","author":"T Biering-S\u00f8rensen","year":"2021","unstructured":"Biering-S\u00f8rensen, T. et al. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). Eur. J. Heart Fail. 23, 1052\u20131056 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"682_CR91","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.jacc.2017.08.012","volume":"70","author":"M Guazzi","year":"2017","unstructured":"Guazzi, M., Bandera, F., Ozemek, C., Systrom, D. & Arena, R. Cardiopulmonary exercise testing: what is its value? J. Am. Coll. Cardiol. 70, 1618\u20131636 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"682_CR92","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jacc.2021.04.065","volume":"78","author":"JR Teerlink","year":"2021","unstructured":"Teerlink, J. R. et al. Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF. J. Am. Coll. Cardiol. 78, 97\u2013108 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"682_CR93","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03759392 (2022)."},{"key":"682_CR94","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink, J. R. et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N. Engl. J. Med. 384, 105\u2013116 (2021).","journal-title":"N. Engl. J. Med."},{"key":"682_CR95","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/jamacardio.2021.4027","volume":"7","author":"G Felker","year":"2021","unstructured":"Felker, G. et al. Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure. a post hoc analysis of data from the GALACTIC-HF randomized clinical trial. JAMA Cardiol. 7, 26\u201334 (2021).","journal-title":"JAMA Cardiol."},{"key":"682_CR96","first-page":"A15707","volume":"140","author":"S Fernandes","year":"2019","unstructured":"Fernandes, S. et al. MYK-491, a novel small-molecule cardiac myosin activator increases cardiac systolic function and preserves mechanical efficiency: pre-clinical in vivo and in vitro evidence [abstract]. Circulation 140, A15707 (2019).","journal-title":"Circulation"},{"issue":"Suppl. 2","key":"682_CR97","doi-asserted-by":"publisher","first-page":"ehaa946.3681","DOI":"10.1093\/ehjci\/ehaa946.3681","volume":"41","author":"K Bell","year":"2020","unstructured":"Bell, K., Anto, A. R., Anderson, R. L., Del Rio, C. L. & Henze, M. Cardiac muscle activation: the role of length dependent activation and the novel myosin activator danicamtiv. Eur. Heart J. 41 (Suppl. 2), ehaa946.3681 (2020).","journal-title":"Eur. Heart J."},{"key":"682_CR98","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.020860","volume":"10","author":"S Shen","year":"2021","unstructured":"Shen, S., Sewanan, L. R., Jacoby, D. L. & Campbell, S. G. Danicamtiv enhances systolic function and Frank-Starling behavior at minimal diastolic cost in engineered human myocardium. J. Am. Heart Assoc. 10, e020860 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"682_CR99","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/ejhf.1933","volume":"22","author":"A Voors","year":"2020","unstructured":"Voors, A. et al. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur. J. Heart Fail. 22, 1649\u20131658 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"682_CR100","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04572893 (2021)."},{"key":"682_CR101","doi-asserted-by":"publisher","first-page":"30773","DOI":"10.1074\/jbc.270.51.30773","volume":"270","author":"R Zhang","year":"1995","unstructured":"Zhang, R., Zhao, J. & Potter, J. D. Phosphorylation of both serine residues in cardiac troponin I is required to decrease the Ca2+ affinity of cardiac troponin C. J. Biol. Chem. 270, 30773\u201330780 (1995).","journal-title":"J. Biol. Chem."},{"key":"682_CR102","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1161\/hh1001.091640","volume":"88","author":"JC Kentish","year":"2001","unstructured":"Kentish, J. C. et al. Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ. Res. 88, 1059\u20131065 (2001).","journal-title":"Circ. Res."},{"key":"682_CR103","first-page":"e558","volume":"142","author":"S Ommen","year":"2020","unstructured":"Ommen, S. et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation 142, e558\u2013e631 (2020).","journal-title":"Circulation"},{"key":"682_CR104","first-page":"66","volume":"17","author":"H Hidaka","year":"1980","unstructured":"Hidaka, H. et al. Calcium-regulated modulator protein interacting agents inhibit smooth muscle calcium-stimulated protein kinase and ATPase. Mol. Pharmacol. 17, 66\u201372 (1980).","journal-title":"Mol. Pharmacol."},{"key":"682_CR105","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1016\/0006-2952(86)90052-3","volume":"35","author":"PJ Silver","year":"1986","unstructured":"Silver, P. J., Pinto, P. B. & Dachiw, J. Modulation of vascular and cardiac contractile protein regulatory mechanisms by calmodulin inhibitors and related compounds. Biochem. Pharmacol. 35, 2545\u20132551 (1986).","journal-title":"Biochem. Pharmacol."},{"key":"682_CR106","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1006\/jmbi.1997.1524","volume":"276","author":"M Osawa","year":"1998","unstructured":"Osawa, M. et al. Solution structure of calmodulin-W-7 complex: the basis of diversity in molecular recognition. J. Mol. Biol. 276, 165\u2013176 (1998).","journal-title":"J. Mol. Biol."},{"key":"682_CR107","doi-asserted-by":"publisher","first-page":"H36","DOI":"10.1152\/ajpheart.00981.2015","volume":"311","author":"BR Thompson","year":"2016","unstructured":"Thompson, B. R., Martindale, J. & Metzger, J. M. Sarcomere neutralization in inherited cardiomyopathy: small-molecule proof-of-concept to correct hyper-Ca2+-sensitive myofilaments. Am. J. Physiol. Heart Circ. Physiol. 311, H36\u2013H43 (2016).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"682_CR108","doi-asserted-by":"publisher","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","volume":"292","author":"RF Kawas","year":"2017","unstructured":"Kawas, R. F. et al. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J. Biol. Chem. 292, 16571\u201316577 (2017).","journal-title":"J. Biol. Chem."},{"key":"682_CR109","first-page":"A20593","volume":"136","author":"CL del Rio","year":"2017","unstructured":"del Rio, C. L. et al. In vivo cardiac effects of mavacamten (MYK-461): evidence for negative inotropy and improved compliance [abstract]. Circulation 136, A20593 (2017).","journal-title":"Circulation"},{"key":"682_CR110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168407","volume":"11","author":"J Stern","year":"2016","unstructured":"Stern, J. et al. A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy. PLoS ONE 11, e0168407 (2016).","journal-title":"PLoS ONE"},{"key":"682_CR111","doi-asserted-by":"publisher","first-page":"H1112","DOI":"10.1152\/ajpheart.00325.2020","volume":"320","author":"L Sewanan","year":"2021","unstructured":"Sewanan, L., Shen, S. & Campbell, S. Mavacamten preserves length-dependent contractility and improves diastolic function in human engineered heart tissue. Am. J. Physiol. Heart Circ. Physiol. 320, H1112\u2013H1123 (2021).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"682_CR112","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1111\/bph.15271","volume":"177","author":"P Awinda","year":"2020","unstructured":"Awinda, P. et al. Effects of mavacamten on Ca2+ sensitivity of contraction as sarcomere length varied in human myocardium. Br. J. Pharmacol. 177, 5609\u20135621 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"682_CR113","doi-asserted-by":"publisher","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","volume":"320","author":"P Awinda","year":"2021","unstructured":"Awinda, P. et al. Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 320, H881\u2013H890 (2021).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"682_CR114","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat1199","volume":"11","author":"C Toepfer","year":"2019","unstructured":"Toepfer, C. et al. Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. Sci. Transl Med. 11, eaat1199 (2019).","journal-title":"Sci. Transl Med."},{"key":"682_CR115","doi-asserted-by":"publisher","first-page":"H715","DOI":"10.1152\/ajpheart.00023.2020","volume":"318","author":"A Sparrow","year":"2020","unstructured":"Sparrow, A., Watkins, H., Daniels, M., Redwood, C. & Robinson, P. Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations. Am. J. Physiol. Heart Circ. Physiol. 318, H715\u2013H722 (2020).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"682_CR116","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"C Ho","year":"2020","unstructured":"Ho, C. et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 75, 2649\u20132660 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"682_CR117","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","volume":"170","author":"S Heitner","year":"2019","unstructured":"Heitner, S. et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann. Intern. Med. 170, 741\u2013748 (2019).","journal-title":"Ann. Intern. Med."},{"key":"682_CR118","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","volume":"13","author":"C Ho","year":"2020","unstructured":"Ho, C. et al. Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy. Circ. Heart Fail. 13, e006853 (2020).","journal-title":"Circ. Heart Fail."},{"key":"682_CR119","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto, I. et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396, 759\u2013769 (2020).","journal-title":"Lancet"},{"key":"682_CR120","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","volume":"143","author":"S Saberi","year":"2021","unstructured":"Saberi, S. et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation 143, 606\u2013608 (2021).","journal-title":"Circulation"},{"key":"682_CR121","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03723655 (2021)."},{"key":"682_CR122","doi-asserted-by":"publisher","first-page":"A9685","DOI":"10.1161\/CIRCULATIONAHA.121.054961","volume":"144","author":"A Owens","year":"2021","unstructured":"Owens, A. et al. Long-term efficacy and safety of mavacamten in patients with non-obstructive hypertrophic cardiomyopathy: interim results from the MAVERICK-LTE cohort of the MAVA-LTE study [abstract]. Circulation 144, A9685 (2021).","journal-title":"Circulation"},{"key":"682_CR123","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","volume":"49","author":"MP Grillo","year":"2019","unstructured":"Grillo, M. P. et al. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica 49, 718\u2013733 (2019).","journal-title":"Xenobiotica"},{"key":"682_CR124","first-page":"A14585","volume":"140","author":"CL del Rio","year":"2019","unstructured":"del Rio, C. L. et al. Chronic treatment with a mavacamten-like myosin-modulator (MYK-581) blunts disease progression in a mini-pig genetic model of non-obstructed hypertrophic cardiomyopathy: in vivo evidence for improved relaxation and functional reserve [abstract]. Circulation 140, A14585 (2019).","journal-title":"Circulation"},{"issue":"Suppl. 2","key":"682_CR125","doi-asserted-by":"publisher","first-page":"ehaa946.3713","DOI":"10.1093\/ehjci\/ehaa946.3713","volume":"41","author":"BS Ferguson","year":"2020","unstructured":"Ferguson, B. S. et al. Acute effects of a mavacamten-like myosin-inhibitor MYK-581 in a feline model of obstructed hypertrophic cardiomyopathy: evidence of improved ventricular filling (beyond obstruction reprieve). Eur. Heart J. 41 (Suppl. 2), ehaa946.3713 (2020).","journal-title":"Eur. Heart J."},{"key":"682_CR126","unstructured":"Australian New Zealand Clinical Trials Registry. ANZCTR https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=378908 (2021)."},{"key":"682_CR127","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nsmb908","volume":"12","author":"J Allingham","year":"2005","unstructured":"Allingham, J., Smith, R. & Rayment, I. The structural basis of blebbistatin inhibition and specificity for myosin II. Nat. Struct. Mol. Biol. 12, 378\u2013379 (2005).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"682_CR128","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.bpj.2014.07.075","volume":"107","author":"C Wilson","year":"2014","unstructured":"Wilson, C., Naber, N., Pate, E. & Cooke, R. The myosin inhibitor blebbistatin stabilizes the super-relaxed state in skeletal muscle. Biophys. J. 107, 1637\u20131646 (2014).","journal-title":"Biophys. J."},{"key":"682_CR129","doi-asserted-by":"publisher","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","volume":"64","author":"C Chuang","year":"2021","unstructured":"Chuang, C. et al. Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J. Med. Chem. 64, 14142\u201314152 (2021).","journal-title":"J. Med. Chem."},{"key":"682_CR130","first-page":"A332","volume":"125","author":"D Hwee","year":"2019","unstructured":"Hwee, D. et al. Pharmacologic characterization of the cardiac myosin inhibitor, CK-3773274: a potential therapeutic approach for hypertrophic cardiomyopathy [abstract]. Circ. Res. 125, A332 (2019).","journal-title":"Circ. Res."},{"key":"682_CR131","doi-asserted-by":"publisher","first-page":"596a","DOI":"10.1016\/j.bpj.2019.11.3225","volume":"118","author":"J Hartman","year":"2020","unstructured":"Hartman, J. et al. Characterization of the cardiac myosin inhibitor CK-3773274: a potential therapeutic approach for hypertrophic cardiomyopathy. Biophys. J. 118, 596a (2020).","journal-title":"Biophys. J."},{"key":"682_CR132","first-page":"A615","volume":"125","author":"D Hwee","year":"2019","unstructured":"Hwee, D. et al. The cardiac myosin inhibitor, CK-3773274, reduces contractility in the R403q mouse model of hypertrophic cardiomyopathy [abstract]. Circ. Res. 125, A615 (2019).","journal-title":"Circ. Res."},{"key":"682_CR133","unstructured":"Cremin, P. et al. In vivo pharmacokinetic characterization of CK-3773274, a novel cardiac myosin inhibitor. AAPS 304702, 887215 (2020)."},{"key":"682_CR134","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04219826 (2021)."},{"key":"682_CR135","unstructured":"BioSpace. Cytokinetics announces positive topline results from cohort 3 of REDWOOD-HCM. BioSpace https:\/\/www.biospace.com\/article\/releases\/cytokinetics-announces-positive-topline-results-from-cohort-3-of-redwood-hcm (2022)."},{"key":"682_CR136","unstructured":"Cytokinetics. Cytokinetics announces positive topline results of REDWOOD-HCM. Cytokinetics https:\/\/ir.cytokinetics.com\/news-releases\/news-release-details\/cytokinetics-announces-positive-topline-results-redwood-hcm (2021)."},{"key":"682_CR137","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2015.03.016","volume":"65","author":"C Fordyce","year":"2015","unstructured":"Fordyce, C. et al. Cardiovascular drug development: is it dead or just hibernating? J. Am. Coll. Cardiol. 65, 1567\u20131582 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"682_CR138","doi-asserted-by":"publisher","first-page":"24691","DOI":"10.1073\/pnas.2006764117","volume":"117","author":"T Tucholski","year":"2020","unstructured":"Tucholski, T. et al. Distinct hypertrophic cardiomyopathy genotypes result in convergent sarcomeric proteoform profiles revealed by top-down proteomics. Proc. Natl Acad. Sci. USA 117, 24691\u201324700 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"682_CR139","doi-asserted-by":"publisher","first-page":"100840","DOI":"10.1016\/j.jbc.2021.100840","volume":"297","author":"T Bunch","year":"2021","unstructured":"Bunch, T. et al. Cardiac myosin-binding protein C interaction with actin is inhibited by compounds identified in a high-throughput fluorescence lifetime screen. J. Biol. Chem. 297, 100840 (2021).","journal-title":"J. Biol. Chem."},{"key":"682_CR140","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.63703","volume":"10","author":"S Nag","year":"2021","unstructured":"Nag, S. & Trivedi, D. To lie or not to lie: super-relaxing with myosins. eLife 10, e63703 (2021).","journal-title":"eLife"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-022-00682-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-022-00682-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-022-00682-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T09:05:07Z","timestamp":1652864707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-022-00682-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":140,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1038\/s41569-022-00682-0","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"assertion":[{"value":"17 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.J.L. is currently a part-time employee of Edgewise Therapeutics. L.A.L. is on the scientific advisory board and has a sponsored research agreement with Bristol Myers Squibb\/MyoKardia. C.C. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}